PMID- 34762577
OWN - NLM
STAT- MEDLINE
DCOM- 20220322
LR  - 20220428
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 21
IP  - 4
DP  - 2022 Apr
TI  - Search of official nationwide database in Japan for adverse events associated 
      with disease-modifying antirheumatic drug therapies: focus on therapies in 
      combination with methotrexate.
PG  - 573-580
LID - 10.1080/14740338.2022.2006180 [doi]
AB  - BACKGROUND: Disease-modifying antirheumatic drugs (DMARDs) are essential for 
      rheumatoid arthritis (RA) therapy. The adverse events (AEs) evaluation should 
      focus on that methotrexate (MTX) is frequently prescribed in combination with 
      others (combination MTX). METHODS: A search of the website of the official 
      Japanese Agency for AEs, including lymphoproliferative disease (LPD), cytopenia, 
      interstitial pneumonia, infectious pneumonia other than Pneumocystis jirovecii 
      pneumonia (PCP) (i-Pn), and PCP, associated with MTX, tacrolimus, adalimumab, 
      tocilizumab, and abatacept therapies reported from 2014 to 2016 was performed. 
      Number of each AE cases and its ratio to total number of AEs cases were examined. 
      Combination MTX was checked for RA cases. RESULTS: A total of 8874 cases were 
      listed. In 3955 MTX cases, LPD was most frequent (36.4%). In any of the other 
      four DMARDs cases, i-Pn was most frequent (4.2 ~ 15.3%); PCP cases showed most 
      frequent combination MTX (94.4%). In total, including cases reported for MTX 
      therapy, 98.2% of LPD and 97.6% of PCP cases had MTX, and less than 90% of the 
      other AEs cases had MTX. CONCLUSION: LPD was by far the most frequent AE 
      associated with MTX therapy. PCP was strongly associated with combination MTX. 
      For any of the other four DMARDs, i-Pn was most frequent.
FAU - Inokuma, Shigeko
AU  - Inokuma S
AUID- ORCID: 0000-0001-9797-1169
AD  - Chiba Central Medical Center; National Center for Global Health and Medicine, 
      Kohnodai Hospital, Chiba, Japan.
LA  - eng
PT  - Journal Article
DEP - 20220314
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Antirheumatic Agents)
RN  - FYS6T7F842 (Adalimumab)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Adalimumab
MH  - *Antirheumatic Agents/adverse effects
MH  - *Arthritis, Rheumatoid/complications/drug therapy
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Japan/epidemiology
MH  - Methotrexate/adverse effects
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Adverse event
OT  - DMARD (disease-modifying antirheumatic drug)
OT  - Pneumocystis jirovecii pneumonia
OT  - lymphoproliferative disease
OT  - methotrexate
EDAT- 2021/11/12 06:00
MHDA- 2022/03/23 06:00
CRDT- 2021/11/11 17:15
PHST- 2021/11/12 06:00 [pubmed]
PHST- 2022/03/23 06:00 [medline]
PHST- 2021/11/11 17:15 [entrez]
AID - 10.1080/14740338.2022.2006180 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2022 Apr;21(4):573-580. doi: 10.1080/14740338.2022.2006180. 
      Epub 2022 Mar 14.